-
Alglucosidase alfa, sold
under the
brand name
Myozyme among others, is an
enzyme replacement therapy (ERT)
orphan drug for
treatment of
Pompe disease...
- cells.
Myozyme falls under the FDA
orphan drug
designation and was
approved under a
priority review.[citation needed] The FDA
approved Myozyme for administration...
-
months and 7 days old and
received treatment at 5 and 4, respectively.
Myozyme, a drug
developed for
treating Pompe disease, was
simultaneously approved...
-
first enzyme replacement therapy for Pompe's
disease -
Alglucosidase alfa (
Myozyme or Lumizyme,
Genzyme Inc) in 2006.
William Canfield's work with
Pompe Disease...
-
August 26, 2009.
Retrieved 2009-09-29. "The
Successful Effort to
Develop Myozyme for
Pompe Disease at
Genzyme FAQs"
Archived January 25, 2010, at the Wayback...
- for
facial wrinkles.
Lumizyme (Alglucosidase alfa), for
Pompe disease.
Myozyme (Alglucosidase alfa), for
Pompe disease.
Sculptra (Polylactic acid), for...
-
control neuroprosthetic limbs. 2006—YT Chen and
Priya Kishnani develop Myozyme as the
first treatment for Pompe’s disease. 2011—Hai Yan
leads a team of...
-
plant was shut down for
production of Cerezyme, Fabrazyme,
Thyrogen and
Myozyme after an
infection of
Chinese hamster ovary cells with
Vesivirus 2117....
-
severe infantile form,
death by 2
years of age. The drug,
eventually named "
Myozyme", was
further developed by
Genzyme and
received the
regulatory marketing...
-
ischiopagus tripus conjoined twins Yuan-Tsong Chen, M.D. (陳垣崇):
inventor of
Myozyme, the
first EMEA- and U.S. Food and Drug Administration-approved treatment...
